禾赛科技 证券研究报告 2025 年 06 月 07 日 收入符合指引，Non-GAAP 同比扭亏为盈，两大业务 稳健发展 25Q1 业绩概览：收入符合指引，利润超预期。25Q1 收入 5.3 亿元， yoy+46.3%；毛利率 41.7%，yoy+2.9pcts；Non-GAAP 净利润 860 万元，同 比扭亏为盈。 海外行业报告 | 行业动态研究 作者 孔蓉 分析师 SAC 执业证书编号：S1110521020002 kongrong@tfzq.com 交付量方面，25Q1 激光雷达总出货量为 195818 台，yoy+231.3%，其中， ADAS 激光雷达出货量为 146087 台，yoy+178.5%。 业务进展：在全球范围内与 23 家 OEM 达成 ADAS 定点合作，涉及 120 多 种车型。 ADAS：海外方面，与一家总部位于日本的全球前五 Tier 1 达成了一项新的 POC 计划；推动与欧洲和日本的四家全球顶级 OEM 和 Tier 1 的五个 POC 项目，其中三个项目在 25Q1 完成。国内方面，近期新增多个车企的新车 型定点合作，包括奇瑞 iCAR、长城汽车欧拉、极氪多款畅销车型 ...

IC 方面，最近一周，小市值、90 天分析师覆盖度、1 个月反转等因子表 现较好，bp、股息率、基于一致预期的标准化预期外盈利等因子表现较 差；最近一月，小市值、季度 ep 一年分位数、90 天分析师覆盖度等因子 表现较好，一年动量、Beta、1 月特异度等因子表现较差；最近一年，小 市值、Fama-French 三因子 1 月残差波动率、1 个月反转等因子表现较 好，一年动量、季度 roa、季度 roe 等因子表现较差。 金融工程 | 金工定期报告 金融工程 证券研究报告 因子跟踪周报： 小市值、成长因子表现较好 - 20250607 因子 IC 跟踪 因子多头组合跟踪 多头组合方面，最近一周，季度 roe 同比、季度营收同比增长、小市值等 因子表现较好，bp、基于一致预期的标准化预期外盈利、bp 三年分位数 等因子表现较差；最近一月，小市值、季度 roe 同比、季度净利润同比增 长等因子表现较好，Beta、bp 三年分位数、基于一致预期的标准化预期 外盈利等因子表现较差；最近一年，小市值、1 个月换手率波动、1 个月 日均换手率等因子表现较好，90 天净上调预期占比、90 天内预期调整均 值、基于一致预期 ...

策略报告 | 投资策略 行业比较周报 证券研究报告 中美会谈下，自主可控板块的节奏与机会 核心结论：6 月 5 日，习近平主席同美国总统特朗普通电话，指出美方应实 事求是看待取得的进展，撤销对中国实施的消极举措；并欢迎特朗普再次访 华。双方经贸协商未完待续，自主可控仍是长期逻辑。自主可控的第一个逻 辑是国家政策多年布局下的积累；自主可控的第二个逻辑是国产替代。穿透 到二级行业，短期可以关注估值处于低位的方向，中期关注产业节奏。估值 方面，前期估值处于低位的板块主要为军工、医药、电子；产业节奏方面， 军工→信创→医药→先进制造。 中美关税会谈破冰后，双方经贸协商未完待续，自主可控仍是长期逻辑。5 月 12 日，中美双方发布《中美日内瓦经贸会谈联合声明》，中美双方关税 中枢回落，后续或仍有多轮协商。一方面，参考 2018 年-2020 年中美经贸谈 判，总共经历了十三轮高级别磋商，历时近两年才签署第一阶段经贸协议。 6 月 5 日，习近平主席同美国总统特朗普通电话，指出美方应实事求是看待 取得的进展，撤销对中国实施的消极举措；并欢迎特朗普再次访华。 另一方面，4 月中旬美方发起的 232 调查和 301 调查仍在 ...

策略报告 | 投资策略 自主可控的第一个逻辑是国家政策多年布局下的积累，顶层设计重视，现代 化产业体系建设要求固链、补链、延链，顶层设计对自主可控领域重视程度 高；自主可控的第二个逻辑是国产替代，即中国对美反制措施可能推升中国 对美进口商品价格，导致对美依赖度较高的商品种类出现供给缺口，国内供 给端替代供给缺口下相关板块有望看到盈利驱动下的业绩改善。 穿透到二级行业，短期可以关注估值处于低位的方向，中期关注产业节奏。 估值方面，前期估值处于低位的板块主要为军工、医药、电子。 产业趋势投资涵盖三个阶段，当前自主可控多数子板块位于阶段一的尾声。 如何能够迈向阶段二开启双击行情？先看产能周期后看业绩，即标的是否开 启大额资本开支以形成产业链的完善可以作为是否进入阶段二的判断，业绩 大面积改善可以作为阶段二拐点出现的确认。 从这个角度，我们判断自主可控各板块产业节奏：军工→信创→医药→先进 制造。 行业比较周报 证券研究报告 中美会谈下，自主可控板块的节奏与机会 核心结论：6 月 5 日，习近平主席同美国总统特朗普通电话，指出美方应实 事求是看待取得的进展，撤销对中国实施的消极举措；并欢迎特朗普再次访 华。双方经贸协 ...

Investment Rating - The report gives a "Buy" rating for the company with a target price of 45.2 CNY, compared to the current price of 36.35 CNY [6]. Core Insights - The company, TaiLing Microelectronics, is a leader in wireless IoT SoC, focusing on cutting-edge technology and binding with industry-leading clients. It has a strong market position in multiple protocol technologies, including low-power Bluetooth and Zigbee [1][3]. - The company has shown significant growth in recent financial performance, with a projected revenue of 844 million CNY in 2024, representing a year-over-year increase of 32.69%, and a net profit of 97.41 million CNY, up 95.71% year-over-year [2][24]. - The company is actively investing in R&D, with R&D expenses reaching 220 million CNY in 2024, accounting for 26.06% of revenue, and a total of 531 million CNY invested over the past three years [2][41]. Summary by Sections Company Overview - TaiLing Microelectronics, established in June 2010, specializes in the R&D, design, and sales of wireless IoT system-level chips, becoming a representative enterprise in the field with a comprehensive product range [1][13]. Financial Analysis - The company's revenue is primarily driven by IoT chips, which are expected to generate 765 million CNY in 2024, a 31.53% increase year-over-year. Audio chips are also experiencing rapid growth, with projected revenue of 76 million CNY, up 61.98% year-over-year [24][26]. - The company has achieved a gross margin of 48.34% in 2025, with IoT chip margins at 47.17% and audio chip margins significantly higher at 58.36% [28][41]. R&D Analysis - The company emphasizes R&D as a driver of growth, with a focus on developing new technologies and products, including the launch of AI chips and advancements in low-power wireless communication standards [35][38]. - In 2024, the company introduced the TL721X series AI chips and the TLEdgeAI-DK development platform, marking its entry into the AIoT era [4][36]. Industry Analysis - The global SoC market is projected to reach approximately 186.48 billion USD by 2025, with a compound annual growth rate of 8.01% from 2025 to 2030 [43][44]. - The low-power Bluetooth chip market is expected to grow from 3.36 billion USD in 2023 to 8.59 billion USD by 2032, indicating a robust demand for wireless communication technologies [48][52].

Investment Rating - The report assigns an "Accumulate" rating for the company, marking it as the first coverage with a target price of HKD 29.50, compared to the current price of HKD 27.2 [5]. Core Viewpoints - The company is recognized as a leading innovation-driven pharmaceutical enterprise, focusing on oncology, anti-infection, central nervous system, metabolic diseases, and autoimmune diseases. It is projected to achieve a revenue of HKD 12.26 billion in 2024, representing a 21% year-on-year growth, and a net profit of HKD 4.372 billion, reflecting a 33% increase [1][5]. - The company has successfully launched multiple innovative drugs, with a strong pipeline that is expected to drive future growth. The sales of innovative drugs are anticipated to continue increasing, with a projected revenue of HKD 9.477 billion in 2024, marking a 38.1% year-on-year growth [16][24]. Summary by Sections 1. Innovation and R&D - The company has established a comprehensive R&D system, employing over 1,800 professionals and creating several national-level research institutions. It has been recognized as a key high-tech enterprise and a national technology innovation demonstration enterprise [14][26]. - The company has eight innovative drugs approved for market, including Amelotin (甲磺酸阿美替尼片) and Fluoromethylnitro (甲磺酸氟马替尼片), which are expected to contribute significantly to revenue growth [16][17]. 2. Market Performance - The sales of Amelotin, the first domestic third-generation EGFR TKI, are projected to grow rapidly, with a compound annual growth rate (CAGR) of 214% from 2020 to 2024, capturing approximately 28% of the total sales of third-generation EGFR TKIs by 2024 [2]. - The company has also seen significant sales growth in Fluoromethylnitro, with a 54% increase in 2023 and a projected 36% growth in 2024 [3]. 3. Future Growth Potential - The company has a robust pipeline with several innovative drugs in various stages of clinical trials, including HS-20089 and HS-20093, which have entered phase II and III trials, respectively [4]. - The company is expanding its market presence through collaborations, such as granting global exclusive licensing rights for HS-10535 to Merck, indicating strong potential for future revenue streams [4][5]. 4. Financial Projections - Revenue forecasts for 2025, 2026, and 2027 are projected at HKD 13.741 billion, HKD 15.567 billion, and HKD 17.374 billion, respectively, with net profits expected to reach HKD 4.746 billion, HKD 5.336 billion, and HKD 5.850 billion [5].

Investment Rating - The report assigns a "Buy" rating for the company with a target price of 45.2 CNY, compared to the current price of 36.35 CNY [6]. Core Insights - The company, TaiLing Microelectronics, is a leader in wireless IoT SoC, focusing on cutting-edge technology and binding with industry-leading clients. It has a strong market position in multiple protocol technologies, including low-power Bluetooth and Zigbee [1][3]. - The company has shown significant growth in recent financial performance, with a projected revenue of 844 million CNY in 2024, representing a year-on-year increase of 32.69%, and a net profit of 97.41 million CNY, up 95.71% year-on-year [2][24]. - The company is heavily investing in R&D, with R&D expenses reaching 220 million CNY in 2024, accounting for 26.06% of revenue, and a total of 531 million CNY invested over the past three years [2][41]. Summary by Sections Company Overview - TaiLing Microelectronics, established in June 2010, specializes in the R&D, design, and sales of wireless IoT system-level chips, becoming a representative enterprise in the field with a comprehensive product range [1][13]. Financial Analysis - The company's revenue is primarily driven by IoT chips, which are expected to generate 765 million CNY in 2024, a 31.53% increase year-on-year. Audio chips are also experiencing rapid growth, with projected revenue of 76 million CNY, up 61.98% year-on-year [24][26]. - The company has achieved a gross margin of 48.34% in 2025, with IoT chip margins at 47.17% and audio chip margins significantly higher at 58.36% [28][41]. R&D Analysis - The company emphasizes R&D-driven growth, with a focus on developing new technologies and products, including the launch of AI chips and advancements in low-power wireless communication standards [35][36]. - In 2024, the company introduced the TL721X series AI chips and the TLEdgeAI-DK development platform, marking its entry into the AIoT era [4][36]. Industry Analysis - The global SoC market is projected to reach approximately 186.48 billion USD by 2025, with a compound annual growth rate of 8.01% from 2025 to 2030 [43]. - The low-power Bluetooth chip market is expected to grow from 3.36 billion USD in 2023 to 8.59 billion USD by 2032, indicating a robust demand for wireless communication technologies [48][52].

Investment Rating - The report assigns an "Accumulate" rating for the company, marking it as the first coverage with a target price of HKD 29.50, compared to the current price of HKD 27.2 [5]. Core Viewpoints - The company is recognized as a leading innovative pharmaceutical enterprise with a focus on oncology, anti-infection, central nervous system, metabolic diseases, and autoimmune diseases. It has shown robust performance with a projected revenue of HKD 12.26 billion for 2024, representing a 21% year-on-year growth, and a net profit of HKD 4.372 billion, reflecting a 33% increase [1][5]. - The company has successfully launched multiple innovative drugs, with significant sales growth in its key products, particularly in the oncology sector, which is expected to account for 66.24% of total revenue by 2024 [17][24]. Summary by Sections 1. Innovation and R&D - The company has established a comprehensive R&D system with over 1,800 professional researchers, focusing on drug discovery and clinical research. It has been recognized as a national high-tech enterprise and a national technology innovation demonstration enterprise [14][26]. - The company has eight innovative drugs approved for market, including Amelotin (甲磺酸阿美替尼片) and Fluoromethine (甲磺酸氟马替尼片), which have shown strong sales performance [16][17]. 2. Sales Performance - The sales of Amelotin are projected to grow at a compound annual growth rate (CAGR) of 214% from 2020 to 2024, capturing approximately 28% of the total sales for third-generation EGFR TKIs by 2024 [2]. - The sales of Fluoromethine increased by 54% in 2023 compared to the previous year, with a projected growth of 36% in 2024 [3]. 3. Future Growth Potential - The company has a robust pipeline with several innovative drugs in various stages of clinical trials, including HS-20089 and HS-20093, which have entered phase II and III trials, respectively [4]. - The company is expanding its market presence with global licensing agreements for its innovative drugs, indicating strong potential for future revenue growth [4][5]. 4. Financial Forecast - The revenue forecast for the company is set at HKD 13.741 billion, HKD 15.567 billion, and HKD 17.374 billion for the years 2025, 2026, and 2027, respectively, with net profits projected at HKD 4.746 billion, HKD 5.336 billion, and HKD 5.850 billion [5].

固定收益 | 固定收益专题 作者 2025 年 06 月 06 日 谭逸鸣 分析师 SAC 执业证书编号：S1110525050005 tanyiming@tfzq.com 唐海清 分析师 SAC 执业证书编号：S1110517030002 tanghaiqing@tfzq.com 唐梦涵 分析师 SAC 执业证书编号：S1110525060002 tangmenghan@tfzq.com 近期报告 1 《固定收益：利率专题-6 月，债市关 键词》 2025-06-04 2 《固定收益：超预期的数据与极致的 可转债定期策略 证券研究报告 6 月，转债择券在"稳" 5 月，权益与转债市场行情复盘 医药与金融地产股领涨，科技 TMT 小幅回调。5 月，科创 50 指数下跌 3.5%，其余 A 股市场主要风格指数小幅收涨，中证 2000 领涨。产业链 看，科技 TMT 跌 0.87%；医药、金融地产板块领涨，分别录得 6.24%、 3.97%涨幅；先进制造、周期、消费板块分别涨 2.52%、2.23%、1.71%。 金融大盘转债领涨大盘，AAA、A 及以下转债表现强势，中评级转债弹性 偏弱。5 月，大盘转债涨 2. ...

公司报告 | 公司专题研究 中材科技（002080） 证券研究报告 新材料领跑先锋，高端卡位有望迎估值重塑 中材科技当前正处于新材料产业化初期，在低介电/低膨胀电子布、高压储氢气瓶 等关键领域实现技术突破，具备 0 到 1 的强劲发展潜力。我们对公司新材料业务 利润贡献进行综合测算，预计 25-27 年特种玻纤布收入分别为 8.5/16.6/24.5 亿元， 对应净利润分别为 1.8/4.9/8.2 亿元（整体净利率分别为 21%/30%/34%），26/27 年 同比分别+173%/+67%。预计 25-27 年公司氢气瓶归母净利润分别为 0.3/0.7/1.5 亿 元，同比分别+82%/+113%/+106%。 估值角度看，参考可比公司，给予新材料板块 26年 25XPE，我们预计 25-27年新 材料利润分别约在 2/6/10 个亿左右，对应 26 年新材料分部市值在 150亿元附近。 主业给予 26 年 16XPE，我们预计未来三年主业利润在 14~16 亿元附近，对应 26 年主业分部市值在 240 亿元附近。综合看公司 26年合理市值在 390 亿元附近，我 们认为公司未来估值将逐渐由传统周期品向 ...